Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:7586073rdf:typepubmed:Citationlld:pubmed
pubmed-article:7586073lifeskim:mentionsumls-concept:C0228174lld:lifeskim
pubmed-article:7586073lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:7586073lifeskim:mentionsumls-concept:C0033613lld:lifeskim
pubmed-article:7586073lifeskim:mentionsumls-concept:C0220781lld:lifeskim
pubmed-article:7586073lifeskim:mentionsumls-concept:C1883254lld:lifeskim
pubmed-article:7586073lifeskim:mentionsumls-concept:C2603343lld:lifeskim
pubmed-article:7586073lifeskim:mentionsumls-concept:C0045900lld:lifeskim
pubmed-article:7586073pubmed:issue9lld:pubmed
pubmed-article:7586073pubmed:dateCreated1995-12-19lld:pubmed
pubmed-article:7586073pubmed:abstractTextVarious 2-aminothiazoles (2a-s and 3a-g) and 2-thiazolecarboxamides (4a-h), possessing a nitrogenous basic moiety at the C-2 position of the thiazole ring, were prepared and tested for anti-anoxic (AA) activity in mice. Among them, N-[2-(4-morpholinyl)ethyl]-4-(3-trifluoromethylphenyl)-2- thiazolecarboxamide hydrochloride (4e, FR108143) (minimum effective doses of 3.2 mg/kg i.p. and 10 mg/kg p.o., respectively) exhibited more potent AA activity than either FK360 or compound 1, each of which has a nitrogenous basic moiety at the C-5 position. The structure-activity relationships with regard to AA activity of this series of compounds are discussed, and the three-dimensional electrostatic potentials (3D-MEP) around the basic nitrogen atom of FK360 and the thiazole derivative (4e) are compared.lld:pubmed
pubmed-article:7586073pubmed:languageenglld:pubmed
pubmed-article:7586073pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7586073pubmed:citationSubsetIMlld:pubmed
pubmed-article:7586073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7586073pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:7586073pubmed:statusMEDLINElld:pubmed
pubmed-article:7586073pubmed:monthSeplld:pubmed
pubmed-article:7586073pubmed:issn0009-2363lld:pubmed
pubmed-article:7586073pubmed:authorpubmed-author:OhkuboMMlld:pubmed
pubmed-article:7586073pubmed:authorpubmed-author:KunoAAlld:pubmed
pubmed-article:7586073pubmed:authorpubmed-author:NakanishiIIlld:pubmed
pubmed-article:7586073pubmed:authorpubmed-author:TakasugiHHlld:pubmed
pubmed-article:7586073pubmed:issnTypePrintlld:pubmed
pubmed-article:7586073pubmed:volume43lld:pubmed
pubmed-article:7586073pubmed:ownerNLMlld:pubmed
pubmed-article:7586073pubmed:authorsCompleteYlld:pubmed
pubmed-article:7586073pubmed:pagination1497-504lld:pubmed
pubmed-article:7586073pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:meshHeadingpubmed-meshheading:7586073-...lld:pubmed
pubmed-article:7586073pubmed:year1995lld:pubmed
pubmed-article:7586073pubmed:articleTitleStudies on cerebral protective agents. VIII. Synthesis of 2-aminothiazoles and 2-thiazolecarboxamides with anti-anoxic activity.lld:pubmed
pubmed-article:7586073pubmed:affiliationNew Drug Research Laboratories, Fujisawa Pharmaceutical Co., Ltd., Osaka, Japan.lld:pubmed
pubmed-article:7586073pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:7586073pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:7586073lld:pubmed